DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
Oprelvekin is an investigational drug.
There have been 4 clinical trials for Oprelvekin. The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2009.
The most common disease conditions in clinical trials are Von Willebrand Diseases, Thrombocytopenia, and Menorrhagia. The leading clinical trial sponsors are Wyeth is now a wholly owned subsidiary of Pfizer, University of Pittsburgh, and University of North Carolina.
Recent Clinical Trials for Oprelvekin
|Study Evaluating The Effects Of Oprelvekin On Cardiac Repolarization In Subjects With Chemotherapy Induced Thrombocytopenia||Pfizer||Phase 2|
|IL-11 in Adults With Von Willebrand Disease Undergoing Surgery||University of North Carolina||Phase 2|
|IL-11 in Adults With Von Willebrand Disease Undergoing Surgery||Wyeth is now a wholly owned subsidiary of Pfizer||Phase 2|